Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12665763 | 0.88 | CHRM1 (0.51) | CHRM1CHRM2MEN1CYP2D6KMT2A | |
| SCHEMBL12395656 | 0.85 | CHRM2 (0.50) | CHRM1CHRM2MEN1CYP2D6KMT2A | |
| SCHEMBL12674256 | 0.71 | CHRM1 (0.43) | CHRM1CHRM2MEN1CYP2D6KMT2A | |
| SCHEMBL12254244 | 0.67 | — | — | |
| SCHEMBL15170714 | 0.67 | — | — | |
| SCHEMBL173191 | 0.67 | — | — | |
| SCHEMBL15444947 | 0.67 | CHRM2 (0.36) | CHRM1CHRM2MEN1CYP2D6KMT2A | |
| SCHEMBL16386083 | 0.67 | CHRM2 (0.36) | CHRM1CHRM2MEN1CYP2D6KMT2A | |
| SCHEMBL20995896 | 0.66 | — | — | |
| SCHEMBL789549 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368244-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9216980-B2 | Methods of use of diazacarbazoles for treating cancer | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-8501765-B2 | Diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110124654-A1 | DIAZACARBAZOLES AND METHODS OF USE | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | CHRM1 3638/4885CHRM2 4042/4885MEN1 945/4885 |
| US-20110124654-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | CHRM1 3310/4885CHRM2 3852/4885MEN1 1132/4885 |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | CHRM1 1154/4885CHRM2 789/4885MEN1 656/4885 |
| US-20150368244-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | CHRM1 3310/4885CHRM2 3852/4885MEN1 1132/4885 |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | CHRM1 1154/4885CHRM2 789/4885MEN1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.